Uniserve Partners with Logistics Reply to Deliver Transformation to Customers Supply Chains
Logistics Reply, a company of the Reply Group specialised in digital solutions for the supply chain, has successfully partnered with Uniserve — the UK’s leading independent provider of logistics and global trade management — to implement a cutting-edge warehouse management system (WMS) to meet the growing demand for scalability, efficiency, and real-time visibility across supply chain operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250414470175/en/
With Logistics Reply’s partnership Uniserve faces successfully the challenges of a growing need for scalability and efficiency.
As the leader in logistics innovation for over 40 years, Uniserve worked with Logistics Reply to implement LEA Reply™, a cloud-native, microservices-based platform developed by Logistics Reply.
LEA Reply™ was selected for its scalability and seamless integration with Uniserve's existing infrastructure. The smooth implementation process and ongoing support have significantly enhanced operations, providing real-time inventory visibility across all sites and improving accuracy rates. Since adopting LEA Reply™, Uniserve has increased operational efficiency and laid the foundation for future growth by implementing a scalable platform designed to support business expansion, with plans to integrate advanced technologies—such as AI, inventory drones, yard management, and dock scheduling—in the future.
“We’ve not only improved operations but set the stage for future growth,” said David Barry, Director of Warehouse and Transport at Uniserve. “With LEA Reply™, we can scale operations while maintaining efficiency and accuracy.”
Simon George, Group IT Director at Uniserve, emphasised the importance of the partnership: “What’s great about Logistics Reply is that they’re not just a software vendor; they’re a true strategic partner. We’re excited to roll out more of their solutions, and we know they’ll be there to support us every step of the way.”
This collaboration exemplifies how innovative solutions can optimise logistics, setting new standards for the industry.
Reply
Reply [EXM, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply supports major European industrial groups in the telecom and media; industry and services; banking and insurance and public sectors in defining and developing business models enabled by the new paradigms of AI, cloud computing, digital media and the internet of things. Reply's services include: consulting, system integration and digital services. www.reply.com
Logistics Reply
Logistics Reply, a Reply Group company, delivers transformative warehouse, store, and supply chain solutions that empower businesses to build efficient, seamlessly connected digital supply chains. By integrating the latest technologies—including artificial intelligence, robotics, wearables, and IoT—Logistics Reply enables seamless interaction between systems, partners, people, and machines. With nearly 30 years of expertise in supply chain technologies and processes, Logistics Reply guides its customers through digital transformation, ensuring rapid time-to-value and lasting operational excellence. www.logistics-reply.com.
Uniserve
Uniserve is the UK’s leading independent logistics and global trade management provider. Founded in 1984, Uniserve has established itself as a pioneer in the logistics industry and employs over 1,500 employees in the UK and Internationally. The business covers every aspect of the supply chain management ecosystem. Seamlessly, combining ocean freight, air freight, road and rail freight services with intelligent warehousing, distribution and supply chain solutions. Where Uniserve sets itself apart is their continuing investment into connected ancillary supply chain services such as customs clearance, consultancy, environmental compliance, finance, bespoke IT systems and education. Uniserve is synonymous with quality, reliability and innovation and a trusted partner to many of the world’s leading businesses.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250414470175/en/
Contacts
Press contact:
Reply
Fabio Zappelli
f.zappelli@reply.com
Tel. +390117711594
Irene Caia
i.caia@reply.com
Tel. +39 02 535761
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom